Glaxo Adds Alli Warning Label In Europe
This article was originally published in The Tan Sheet
Executive Summary
The European Union health authority recommended GlaxoSmithKline add a warning to alli nonprescription weight-loss drug, advising patients taking levothyroxine or antiepileptic drugs, or those with kidney disease, to consult a doctor before using
You may also be interested in...
FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
In Europe, Centralized OTC Switch Still Has A Few Bugs
The European Union's diversity means that when it comes to the new centralized procedure for Rx-to-OTC switches, there are several details yet to be ironed out, according to OTC industry executives